Loading viewer...
investor_presentation
Format: PDF investor_presentation
Immutep Limited presents its immunotherapy pipeline focused on LAG-3 for cancer and autoimmune disease treatment. The company highlights its lead asset eftilagimod alpha (efti), demonstrating compelling clinical efficacy in combination with established cancer therapies across multiple indications including non-small cell lung cancer, breast cancer, and head and neck squamous cell carcinoma. With multiple partnerships and collaborations with large pharmaceutical companies, Immutep has a well-funded position with cash runway extending to early 2026.
investor_presentation
63 Pages
Immutep AIPAC Phase IIb Eftilagimod Alpha Breast Cancer Biomarker Results
conferenceconference
1 Pages
investor_presentation
36 Pages
Cullinan Oncology
Adani Energy Solutions Limited Credit Presentation 2024
investor_presentationinvestor_presentation
47 Pages
Adani Energy Solutions Limited
investor_presentation
Siemens